Intra-Cellular Therapies Inc. (ITCI) Given Consensus Rating of “Hold” by Brokerages
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) has been assigned an average rating of “Hold” from the nine analysts that are currently covering the stock. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $39.83.
ITCI has been the topic of a number of research reports. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $57.00 target price on shares of Intra-Cellular Therapies in a research report on Tuesday, September 13th. Leerink Swann reaffirmed a “buy” rating and set a $95.00 target price on shares of Intra-Cellular Therapies in a research report on Thursday, August 11th. Royal Bank Of Canada dropped their target price on shares of Intra-Cellular Therapies from $74.00 to $49.00 and set an “outperform” rating on the stock in a research report on Thursday, September 29th. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $42.00 price target on the stock in a report on Wednesday, June 29th. Finally, RBC Capital Markets reissued an “outperform” rating and issued a $49.00 price target (down previously from $74.00) on shares of Intra-Cellular Therapies in a report on Friday, September 30th.
Several large investors have recently modified their holdings of the stock. Royal Bank of Canada increased its stake in shares of Intra-Cellular Therapies by 23.1% in the second quarter. Royal Bank of Canada now owns 2,684 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 504 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of Intra-Cellular Therapies during the second quarter valued at approximately $155,000. Mycio Wealth Partners LLC increased its stake in shares of Intra-Cellular Therapies by 14.3% in the second quarter. Mycio Wealth Partners LLC now owns 4,398 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 550 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of Intra-Cellular Therapies by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 4,532 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 546 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Intra-Cellular Therapies by 29.3% in the second quarter. Legal & General Group Plc now owns 5,282 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 1,197 shares in the last quarter. Institutional investors own 70.31% of the company’s stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/intra-cellular-therapies-inc-itci-given-consensus-rating-of-hold-by-brokerages.html
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) traded up 0.61% during mid-day trading on Monday, reaching $13.11. 519,084 shares of the company traded hands. The stock’s 50 day moving average is $32.73 and its 200 day moving average is $36.28. Intra-Cellular Therapies has a 52-week low of $12.85 and a 52-week high of $59.96. The stock’s market capitalization is $567.02 million.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.08. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.02 million. During the same period last year, the firm posted ($0.61) EPS. The company’s revenue was up 283.3% compared to the same quarter last year. On average, analysts anticipate that Intra-Cellular Therapies will post ($3.19) earnings per share for the current year.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.